TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02189720
Drug: Amifampridine Phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphate given based on Investigator assessment of optimal neuromuscular benefit. In adult patients \> 16 years of age, Doses ranged from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day and in pediatric patients age \< 16 years the maximum daily dose was 60 mg/day. No single dose to exceed 20 mg.
Study: NCT05075824
Drug: Crovalimab
Normalized name: Crovalimab
DrugBank: Crovalimab (DB16128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.
Study: NCT04345796
Drug: Carvedilol+Empagliflozin
Normalized name: Empagliflozin
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group A
Study: NCT04345796
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B
Study: NCT04345796
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group C
Study: NCT05787639
Drug: Evorpacept
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
Study: NCT06788756
Drug: Placebo in combination with Cytarabine Injection
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
Study: NCT06788756
Drug: Liposomal Annamycin Injection in combination with Cytarabine Injection
Normalized name: cytarabine liposome Injection
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
Study: NCT06788756
Drug: Liposomal Annamycin Injection in combination with Cytarabine Injection
Normalized name: cytarabine liposome Injection
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
Study: NCT06788756
Drug: Liposomal Annamycin for Injection in combination with Cytarabine Injection.
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).
Study: NCT05205811
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
Study: NCT05205811
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Zonisamide (100 mg/daily) for 7 weeks.
Study: NCT05205811
Drug: Placebo bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo bupropion for 7 weeks.
Study: NCT05205811
Drug: Placebo zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo zonisamide for 7 weeks.
Study: NCT04750460
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.
Study: NCT06775834
Drug: HRS-1893
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-1893 tablets.
Study: NCT06788340
Drug: PK-model to decide when to dose Vedolizumab and Ustekinumab
Normalized name: Vedolizumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.
Study: NCT06797674
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT06102902
Drug: BET Bromodomain Inhibitor ZEN-3694
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06102902
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04837703
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (\< 50 mg) or preferably no calcium.
Study: NCT05644665
Drug: Ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05844618
Drug: Triamcinolone Acetonide (Aristocort® C)
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
Study: NCT05924165
Drug: 5mg Oxycodone, Q6 PRN
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone is an opioid that is used to relieve moderate to severe pain.
Study: NCT06354660
Drug: Retatrutide
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06334120
Drug: Darolutamide (Nubeqa, BAY1841788)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
Study: NCT05909904
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05276570
Drug: ARO-RAGE
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single or multiple doses of ARO-RAGE by inhalation of nebulized solution
Study: NCT06072482
Drug: Avacopan
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05959447
Drug: Camlipixant
Normalized name: Camlipixant
DrugBank: Camlipixant (DB19217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camlipixant will be administered
Study: NCT05959447
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate will be administered
Study: NCT05959447
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil will be administered.
Study: NCT06006702
Drug: TYRA-300-B01
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
Study: NCT05909904
Drug: BGB-A425
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06174402
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 200 mg/day
Study: NCT06174402
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 13-15mg/kg/day
Study: NCT05960578
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05960578
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given SC
Study: NCT06028321
Drug: Part 1 Group 1 Regime A (ACM-001.1)
Normalized name: Meningococcal group A polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group A (DB13889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo, and pindolol tablets for oral use.~Subjects randomised to Regimen A received placebo tablets to match the tablet number received by subjects in Regimen B.
Study: NCT06028321
Drug: Part 1 Group 2 Regimen C (Pindolol)
Normalized name: Meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Pindolol tablets for oral use.
Study: NCT06028321
Drug: Part 2 Group D (Pindolol)
Normalized name: Vitamin D-2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Pindolol tablets for oral use. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study: NCT04681638
Drug: Crystalloid Solutions
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
Study: NCT06613243
Drug: Esketamine 0.2 mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study: NCT06613243
Drug: Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study: NCT06613243
Drug: Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
Study: NCT06495424
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeat applications every 12 weeks in patients with PDPN of the feet.
Study: NCT06189391
Drug: CN201
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In fixed dosing group, patients will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks, followed by 1 week off for 4 weeks as a treatment cycle.~Patients in step-up dosing group will be administered with CN201 by intravenous infusion on Day 1 of each week for 3 consecutive weeks (without treatment off week). Patients who complete 4 treatment cycles and remain in complete response (CR) or partial response (PR) may also be considered by the investigator for 2-weekly dosing (Q2W, window: -3 days, 4 weeks in a treatment cycle), which allows further comparative observation of the long-term efficacy and safety of Q2W. Treatment will be continued untill confirmed disease progression, intolerable toxicity, withdrawal of consent, patient being lost to follow-up, receipt of other antitumor therapy, death or study termination by sponsor, whichever occurs earlier, or up to 12 months in the absence of disease progression.
Study: NCT06612151
Drug: YL201
Normalized name: Lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.
Study: NCT06612151
Drug: topotecan hydrochloride for injection
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan hydrochloride will be administered intravenously per prescribing information.
Study: NCT06136559
Drug: Nemtabrutinib
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06136559
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT06136559
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT05494762
Drug: BGB-B167
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05494762
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05081518
Drug: Lu AG06466
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AG06466 - capsule
Study: NCT06028321
Drug: Part 2 Group E (ACM-001.1)
Normalized name: (E)-2-butenedioic acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study: NCT06028321
Drug: Part 2 Group F (ACM-001.1 )
Normalized name: 2-F-ARAA
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ACM-001.1 immediate release tablets for oral use and matching placebo. Subjects were dosed over a four day treatment period twice daily. Subjects receiving ACM-001.1 in regimens E, F and G also received placebo tablets to match the tablet number received by subjects receiving pindolol in Regimen D.
Study: NCT06246110
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 inhibitor
Study: NCT06246110
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy
Study: NCT06246110
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemotherapy
Study: NCT06246110
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT05030519
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
Study: NCT04730544
Drug: Nivolumab 480mg + Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
Study: NCT04730544
Drug: Nivolumab 240 mg + Ipilimumab
Normalized name: nivolumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
Study: NCT06566820
Drug: Aroxybutynin and Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed Dose Combination
Study: NCT06453213
Drug: Cenobamate
Normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a certain type of seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day).~The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a certain type of seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day).
Study: NCT05620836
Drug: Povorcitinib
Normalized name: Povorcitinib
DrugBank: Povorcitinib (DB18855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, Tablet
Study: NCT05856526
Drug: Spesolimab - solution for infusion
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT05856526
Drug: Placebo matching to spesolimab - solution for infusion
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT05856526
Drug: Spesolimab - solution for injection
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT05856526
Drug: Placebo matching to spesolimab - solution for injection
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT04899661
Drug: Molidustat (Musredo, BAY85-3934)
Normalized name: Molidustat
DrugBank: Molidustat (DB15642)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Tablets, administered orally at the discretion of investigators
Study: NCT06230757
Drug: Psilocybin 25mg
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg psilocybin capsule
Study: NCT04938817
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT06435858
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg
Study: NCT05689645
Drug: Sterilizing water for injection
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The composition of this product is water for injection, and the dosage volume is 2mL for intramuscular injection.~Medication course: The first stages were administered once a day for 7 days and second stages were administered once a day for 14 days. The third stage was administered once a day for 28 days.
Study: NCT04952753
Drug: NIS793
Normalized name: Anti-tgf-beta monoclonal antibody nis793
DrugBank: Nisevokitug (DB17561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
Study: NCT04952753
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered IV
Study: NCT04952753
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug tislelizumab will be administered intravenously (IV).
Study: NCT05938270
Drug: Saruparib (AZD5305)
Normalized name: Saruparib
DrugBank: Saruparib (DB18982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saruparib (AZD5305) given orally once daily
Study: NCT05938270
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
Study: NCT06637306
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
Study: NCT06637306
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
Study: NCT06637306
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
Study: NCT06637306
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
Study: NCT06209177
Drug: ARO-CFB
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-CFB for sc injection
Study: NCT06555796
Drug: Xaluritamig
Normalized name: Xaluritamig
DrugBank: Xaluritamig (DB18137)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06521762
Drug: Etrasimod
Normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day oral tablet
Study: NCT05657496
Drug: Triamcinolone Acetonide 40 mg/ml Inj, Susp
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prepared in clinic by physician or medical staff